Trial · NCT06904170
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
NCT06904170, Phase 2, Phase 3, Recruiting, UNICANCER
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma. Trials, record NCT06904170. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06904170
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
- NCT number
- NCT06904170
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 196 participants, estimated
- Lead sponsor
- UNICANCER
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab Plus Tremelimumab, HAIC (GEMOX)
- First posted
- 2025-04-01
- Last updated
- 2026-02-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase II : Objective Response Rate according to RECIST 1.1 | From date of randomization until the date of first documented progression, and up to 6 months after the inclusion of the last patient | The proportion of patients with Complete Response or Partial Response according to RECIST 1.1 |
| Primary | Phase III : Overall Survival | From date of randomization to the date of death, up to 18 months after the randomization of the last patient | The time between Randomisation and death from any cause |
| Secondary | Safety of the combination of immune therapy and HAIC | From the first study treatment administration to 30 days after the last administration of study treatment | Will be assessed : * the frequency of limiting toxicities (LT) occuring during the combination phase (the first 12 weeks). LT are defined as any toxicity related to the experimental drug, that leads to definitive treatment discontinuation. * the frequency and severity of treatment-related adverse events as per NCI-CTCA v5.0 |
| Secondary | Progression-Free Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first, up to 18 months after the inclusion of the last patient | Defined as the delay between the date of randomization and the date of the first progression or death from any cause. Progression will be assessed via RECIST 1.1 and mRECIST. |
| Secondary | Phase II : Overall Survival | From date of randomization to the date of death, up to 18 months after the randomization of the last patient | Defined as the delay between randomization and death from any cause. |
| Secondary | Phase III : Objective Response Rate | From date of randomization until the date of first documented progression, and up to 6 months after the inclusion of the last patient | Defined as the proportion of patients with Complete Response or Partial Response according to RECIST 1.1 |
| Secondary | Health-Related Quality of Life (HRQoL) measured by the EORTC QLQ-C30 questionnaire | From date of randomization and until the date of first documented progression, up to 18 months after the inclusion of the last patient | Quality of life will be assessed with questionnaire EORTC QLQ-C30, at baseline and every 2 months until disease progression or study termination |
| Secondary | Health-Related Quality of Life (HRQoL) measured by the EORTC HCC-18 questionnaire | From date of randomization and until the date of first documented progression, up to 18 months after the inclusion of the last patient | Quality of life will be assessed with questionnaire EORTC HCC-18, at baseline and every 2 months until disease progression or study termination |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06904170
GET https://conductscience.org/api/trials/v1/NCT06904170/registered